Tags & Categorías

La EAHP defiende la sustitución de biológicos por biosimilares en situaciones previamente pactadas

La Asociación Europea de Farmacéuticos de Hospital (EAHP) ha hecho pública la actualización de su posicionamiento (Position Paper) sobre biosimila...

2 New Studies Highlight Safety, Efficacy, PK of Subcutaneous CT-P13

Celltrion, maker of biosimilar infliximab CT-P13 (Remsima, Inflectra), has recently submitted an application to the European Medicines Agency for a su...

Mandatory and non-mandatory switching for biosimilars

Glintborg and co-authors responded to the comments made by Marc Scherlinger and Thierry Schaeverbeke on their paper ‘To switch or not to switch’, ...

Biosimilar Pegfilgrastim, Pelmeg, Launches in the United Kingdom

Napp Pharmaceuticals has announced the UK launch of Pelmeg, a biosimilar pegfilgrastim developed by Cinfa Biotech and subsequently acquired by Mundiph...

La penetración de los biosimilares está en el 3% del mercado hospitalario

La penetración de los medicamentos biosimilares en el mercado está siendo lenta, aunque constante. En 2018 estos productos alcanzaron un 3% de cuota...

Pfenex and Alvogen to Partner on Teriparatide Follow-on

Pfenex and Alvogen announced this week that they have entered into agreements to develop and commercialize PF708, a follow-on teriparatide product ref...

Spanish pharmacists publish biosimilar position statement

The Spanish Society of Hospital Pharmacy (Sociedad Española de Farmacia Hospitalaria, SEFH) has published a position statement on the use of biosimil...

Nurses, Patients Prefer Biosimilar Adalimumab's Autoinjector, Survey Finds

A recent study aimed to evaluate patients’ and nurses’ preferences for the autoinjector for a biosimilar adalimumab marketed as Imraldi in the Eu...

EC approval for pegfilgrastim biosimilar Fulphila

In January 2019, the pegfilgrastim biosimilar, Fulphila, received European Commission (EC) approval.

Ahead of an FDA Decision on Its Pegfilgrastim Biosimilar, Sandoz Sues Amgen

This month, biosimilar developer Sandoz filed suit against Amgen, asking the United States district court for the Northern District of California for ...